Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
for Metastatic Nasopharyngeal Carcinoma
Drug: Relatlimab
83 locations incl. Dublin
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT06029270·Phase 2·Recruiting